Skip to content

NewAmsterdam Pharma

US · NAMS #2583 by market cap Listed 1970
18.41 -1.10 -5.64%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 3.83 In line with history 60th percentile
5-year average 3.08 · #351 of 514 in Biotechnology
P/E ratio -11.92 Cheap vs history 27th percentile
5-year average -9.44 · forward -9.27
P/S ratio 93.13 In line with history 63rd percentile
5-year average 90.04 · forward 103.13 · #291 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
NewAmsterdam Pharma (NAMS) 2.21B -10.89 3.50 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★☆ Fair value25.71 Economic moatNone UncertaintyVery High

Trading 39.6% below Morningstar's fair value estimate.

Fair value

NewAmsterdam Pharma Co NV receives a 4-star quantitative star rating, indicating our belief that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 22% discount to our quantitative fair value estimate of $25.71 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The company's valuation metrics strengthen our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its price to cash ratio of 3.6, which falls in the bottom 40% globally. Even if the company were to encounter financial distress, its cash balances could allow it to maneuver effectively. We believe this is a sign that shares could be undervalued.

Alternatively, the company's liquidity is potentially concerning. Excessive liquidity may suggest inefficient capital use or limited investment opportunities. The firm's median trading volume over the past 60 days, a core component of liquidity, lies in the top 30% globally. High trading volumes could indicate a sharp change in business model or a new growth trajectory of the business. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. However, its financial health score is strong, suggesting that the company should be well positioned to weather tough times.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

NewAmsterdam Pharma discussion 0 comments

Add a comment